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A B S T R A C T
Introduction: Nonalcoholic steatohepatitis (NASH) is a sub-classification of nonalcoholic fatty liver disease
(NAFLD) characterized by increased risk of progressive liver fibrosis. Cenicriviroc (CVC) is a novel, orally ad-
ministered, potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver
fibrosis in adults with NASH.
Methods and analysis: Efficacy and safety of CVC will be comprehensively evaluated in a global, Phase 3, mul-
ticenter, randomized, double-blind, placebo-controlled study (AURORA, NCT03028740) of subjects with NASH
and Stage F2 or F3 fibrosis. Approximately 2000 adults (Part 1, 1200 subjects; Part 2, 800 additional subjects)
aged 18–75 years with histological evidence of NASH with Stage F2 or F3 fibrosis (NASH Clinical Research
Network classification system) will be randomized 2:1 to CVC 150 mg or placebo orally once daily. Primary
efficacy endpoints will include the proportion of subjects with ≥1-stage improvement in liver fibrosis and no
worsening of steatohepatitis at Month 12 relative to screening (Part 1), and time to first occurrence of any
adjudicated event: death; histopathologic progression to cirrhosis; liver transplant; Model of End-Stage Liver
Disease score≥ 15; ascites; hospitalization due to liver decompensation (Part 2). Patient-reported outcomes will
assess changes in health outcomes from baseline (Chronic Liver Disease Questionnaire - NAFLD; Work
Productivity and Activity Impairment in NASH; 36-Item Short Form Health Survey version 2). Adverse events
will be assessed throughout the study. As there are currently no approved treatments indicated for NASH, the
AURORA CVC Phase 3 study addresses an unmet medical need.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a common, often “silent”
liver disease associated with metabolic disorders [1]. It is characterized
by accumulation of fat in the liver (steatosis), unrelated to excessive
alcohol consumption [2–5]. Up to 44% of individuals with NAFLD will
progress to nonalcoholic steatohepatitis (NASH) [6–8], which is char-
acterized by steatosis, hepatocellular ballooning, and lobular in-
flammation, and can progress to cirrhosis and hepatocellular carcinoma
[9–11]. The increasing prevalence of obesity-related disorders has
contributed to a rapid increase in the prevalence of NASH (3–5% in the
US) [12], now the most common indication for liver transplantation in
women in the US and second most common in men [13]. The increasing
burden of NASH on patients and healthcare providers [14], combined
with an absence of approved therapies, represents an unmet medical
need.
Liver inflammation is regulated by chemokines that control the
activities and migration of various hepatic and immune cells [15]. The
CeC chemokine receptor types 2 (CCR2) and 5 (CCR5) and their re-
spective ligands (CCL2 and CCL3–5) are involved in the pathogenesis of
liver inflammation and fibrosis, contributing to the development of
NAFLD and NASH [15–17]. CCL2 and its receptor CCR2 become up-
regulated in the liver, promoting macrophage accumulation, in-
flammation, fibrosis, and steatosis [15], while CCL5 exhibits profibrotic
activity and also induces steatosis and pro-inflammatory factors in he-
patocytes via the CCR5 receptor [16]. In mouse models, CCR2 [18,19]
or CCR5 [20,21] inhibition resulted in a reduction in liver fibrosis and
de-activation of immune cells. Therefore, CCR2 and CCR5 have been
established as promising therapeutic targets for NASH.
Cenicriviroc (CVC) is a novel, orally administered, and potent CCR2
and CCR5 receptor antagonist which is currently in clinical develop-
ment for the treatment of liver fibrosis in adults with NASH, having
received Fast Track designation by the US Food and Drug
Administration. CVC demonstrated antifibrotic effects in animal models
[22–26], and also blocked CCR2 and CCR5 in Phase 2 studies in sub-
jects with human immunodeficiency virus (HIV) [27,28]. In the Phase
2b CENTAUR study in adults with NASH and liver fibrosis [29], CVC
treatment improved fibrosis, the histological feature consistently linked
with clinical outcomes in NAFLD [30–32], and was twice as likely to
provide an antifibrotic benefit compared with placebo [33]. Among the
Phase 3 target population in the Phase 2b study, subjects with NASH
and Stage F2 or F3 liver fibrosis, 28% of CVC-treated subjects achieved
≥1 stage improvement in liver fibrosis without worsening of NASH
compared to 16% on placebo (odds ratio 2.2; 95% confidence interval
[CI] 1.00–4.69; p = .049) [33]; most maintained efficacy at Year 2,
with a greater effect observed in those with more advanced fibrosis
[33]. Overall, CVC has shown a favorable safety and tolerability profile
in> 1200 subjects [34], including those with cirrhosis and hepatic
impairment [33,35].
Following these promising Phase 2 results, the AURORA Phase 3
study aims to evaluate and confirm the efficacy and safety of CVC for
the treatment of liver fibrosis in adults with NASH.
2. Study design
2.1. Structure
AURORA (NCT03028740) is a global, Phase 3, multicenter, rando-
mized, double-blind, placebo-controlled study, which will be conducted
in two parts (Fig. 1). In Part 1, approximately 1200 subjects with his-
tological evidence of NASH and Stage F2 or F3 fibrosis will be rando-
mized 2:1 to CVC 150 mg orally or placebo once daily to evaluate a
surrogate histology endpoint at Year 1. There will be approximately
2000 subjects in Part 2, including approximately 1200 subjects from
Part 1 and 800 newly randomized subjects, also with histological evi-
dence of NASH and Stage F3 fibrosis. A target of at least 60% of subjects
with Stage F3 fibrosis will be enrolled in the study overall. Part 2 will
assess clinical outcomes and will end when adjudicated events have
been accrued in approximately 367 individual subjects across both
parts of the study. The treatment duration is estimated to be 60 months
for subjects participating in the study and will vary depending on the
time taken to accrue the necessary number of adjudicated events.
2.2. Study endpoints
The objective of Part 1 is to demonstrate the superiority of CVC
compared to placebo on liver histology at Month 12 relative to
screening. The primary endpoint is the proportion of subjects with
improvement in liver fibrosis by ≥1 stage AND no worsening of stea-
tohepatitis, defined as no worsening of lobular inflammation or hepa-
tocellular ballooning grade. The key and other secondary endpoints are
shown in Table 1, with exploratory objectives including the proportion
of subjects with resolution of steatohepatitis AND no worsening of fi-
brosis, the proportion of subjects with improvement in fibrosis by ≥1
stage (using a modified Ishak system), the proportion of subjects with
histopathologic progression to cirrhosis, the proportion of subjects with
hepatic decompensation, and the change from baseline in non-invasive
assessments of liver fibrosis.
The objective of Part 2 is to demonstrate the superiority of CVC
compared to placebo on the composite endpoint of histopathologic
progression to cirrhosis (NASH Clinical Research Network [CRN] clas-
sification system, Stage F4), liver-related clinical outcomes, and all-
cause mortality. The primary and secondary endpoints are shown in
Table 1, with exploratory objectives including: the time to first occur-
rence of ascites (requiring intervention) or hospitalization for onset of
variceal bleeding, hepatic encephalopathy (West Haven Stage ≥2), or
spontaneous bacterial peritonitis; the proportion of subjects with his-
topathologic progression to cirrhosis (NASH CRN Stage F4); and the
effect of CVC compared to placebo on liver histology.
2.3. Sample size
The planned sample size for Part 1 (800 subjects in the CVC arm and
400 in the placebo arm) is based on the primary binary endpoint at
Month 12, and is expected to provide 84% power to demonstrate strong
evidence with a single study (two-sided significance level of 0.0012),
assuming a 15% response rate for the placebo arm and a 25% response
rate for CVC (based on the effect observed in the Phase 2b CENTAUR
study results).
The sample size for the Part 2 primary endpoint analysis is based on
an estimated event-free survival rate of 80% for the placebo group
(based on observed cumulative survival free of transplants in patients
with NASH and any stage of fibrosis, and taking into account that
subjects enrolled in AURORA will have Stages F2 or F3 fibrosis), and a
hazard ratio of 0.62 by the end of the study, corresponding to a median
event-free survival time of approximately 15 years for placebo and
25 years for CVC [30]. A total of 2000 subjects enrolled for an overall
study duration of 8 years, with dropout rate estimated at 20%, is ex-
pected to lead to approximately 367 events. This calculation gives 85%
power to demonstrate strong evidence of superiority of CVC over pla-
cebo (two-sided 0.00125 significance level), and 99% power to test the
superiority of CVC over placebo (two-sided 0.05 significance level).
East® 6.4 software (Cytel, Cambridge, MA, USA) was used for the cal-
culation.
3. Study procedures
3.1. Recruitment and screening processes
Centers in North, Central, and South America, Europe, and Asia
Pacific will participate in the AURORA study. The study will be con-
ducted in accordance with the Declaration of Helsinki, International
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Conference on Harmonisation E6 Good Clinical Practice guidelines, and
all local and national regulations, and will be approved by the relevant
institutional review board or independent ethics committee. Written,
informed consent will be required from all subjects prior to participa-
tion.
Screening will take place no>12 weeks before the baseline visit. In
Part 2, a screening visit will only be required for newly enrolled sub-
jects.
3.2. Eligibility
Key inclusion criteria are: adults aged 18–75 years with histo-
pathological evidence of NASH based on central reading of biopsy
slides, with Stages F2 or F3 liver fibrosis for subjects in Part 1 (defined
using NASH CRN system) and Stage F3 liver fibrosis for subjects newly
enrolled in Part 2 (NASH CRN), at screening or based on historical
evidence (if the following conditions are met: historical biopsy obtained
no> 6 months prior to the first day of screening; hepatic tissue avail-
able for central histological evaluation; no new pharmacological in-
tervention for NASH made during the period between the biopsy and
screening; and subjects have been metabolically stable since the
biopsy); females of child-bearing potential and males must use at least
two approved methods of contraception throughout the study and for
30 days after stopping the study drug; females who are postmenopausal
must have documentation of cessation of menses for ≥12 months
without an alternative medical cause.
Key exclusion criteria include: a history or presence of cirrhosis
(NASH CRN Stage F4) and/or hepatic decompensation including as-
cites, hepatic encephalopathy, or variceal bleeding; other known causes
of chronic liver disease; prior or planned liver transplantation; HIV-1 or
HIV-2 infection; inability to undergo a liver biopsy; hepatitis B surface
antigen-positive; alcohol consumption> 21 units/week for males or
14 units/week for females (one unit of alcohol is defined in this study as
a half pint of beer [285 mL; 9.64 oz], one glass of spirits [25 mL;
0.85 oz], or one glass of wine [125 mL; 4.23 oz]); > 5 × upper limit of
normal (ULN) aspartate aminotransferase (AST) [ULN range: 31–37 U/
L] or alanine aminotransferase (ALT) [ULN range: 32–43 U/L] and
glycated hemoglobin>9% (> 75 mmol/mol) at screening; total bilir-
ubin> 1.3 mg/dL (> 22.2 μmol/L); international normalized ratio >
1.3; and Model for End-Stage Liver Disease (MELD) score > 12.
Concomitant medications will be allowed unless they are in-
vestigational or if they are CYP3A4 substrates with a narrow ther-
apeutic index, or strong inducers or inhibitors of CYP3A4 or CYP2C8.
The use of pioglitazone or vitamin E (> 400 IU/day) will be disallowed
based on the potential for confounding effect on the study efficacy
endpoints [36].
3.3. AURORA Toolbox
A major challenge encountered in previous clinical trials, including
CENTAUR, was the high screening failure rate observed in NASH pa-
tients. This may be up to 80% of screened cases, the majority of which
fail due to insufficiently meeting the required histological criteria for
study entry. To mitigate this, a non-invasive testing strategy was
Fig. 1. AURORA study design schematic.
aApproximately 2000 subjects will be randomized; the first ~1200 subjects will be included in the analysis of endpoints in Part 1 and all subjects will be included in
the analysis of endpoints in Part 2.
CVC, cenicriviroc.
Table 1
Study endpoints.
Part 1 Part 2
Primary efficacy endpoints
Proportion of subjects with improvement in fibrosis by ≥1 stagea AND no worsening of
steatohepatitisb on liver histology at Month 12 relative to the screening biopsy
Time to first occurrence of any of the following adjudicated events: death (any cause);
histopathologic progression to cirrhosisa; liver transplant; MELD score ≥ 15; ascites
(requiring intervention); and hospitalization due to liver decompensation
Secondary efficacy endpoints
Key secondary efficacy endpoint: Proportion of subjects with improvement in fibrosis by
≥2 stages AND no worsening of steatohepatitisb on liver histology at Month 12
relative to the screening biopsy
Proportion of subjects with improvement in fibrosis by≥2 stages AND no worsening
of steatohepatitisb on liver histology at Month 12 relative to the screening biopsy
(subjects newly randomized in Part 2 only)
Proportion of subjects with improvement in fibrosis by ≥1 stage, regardless of effect on
steatohepatitis, at Month 12 relative to the screening biopsy
Proportion of subjects with improvement in fibrosis by≥1 stage, regardless of effect
on steatohepatitis, at Month 12 relative to the screening biopsy (subjects newly
randomized in Part 2 only)
Proportion of subjects with improvement in fibrosis by≥2 stages, regardless of effect on
steatohepatitis, at Month 12 relative to the screening biopsy
Proportion of subjects with improvement in fibrosis by≥2 stages, regardless of effect
on steatohepatitis, at Month 12 relative to the screening biopsy (subjects newly
randomized in Part 2 only)
Proportion of subjects with improvement in fibrosis by ≥1 stage AND no worsening
of steatohepatitisb on liver histology at Month 12 relative to the screening biopsy
(subjects newly randomized in Part 2 only)
Four further secondary endpoints will analyze all of the above sets of criteria using
the Month 60 biopsy (all subjects)
MELD, Model of End-Stage Liver Disease; NASH CRN, Nonalcoholic Steatohepatitis Clinical Research Network.
a NASH CRN system used to classify fibrosis stage in all primary and secondary efficacy endpoints.
b No worsening of lobular inflammation or hepatocellular ballooning grade.
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developed using a number of readily available and cost-effective
screening tools.
As a result, the AURORA Toolbox, a novel online portal, will be
made available to investigators as a non-mandatory pre-screening tool.
The Toolbox aids assessment of subjects for clinically significant NAFLD
based on clinical characteristics, non-invasive serum fibrosis measures
(fibrosis-4 index [FIB-4]; NAFLD fibrosis score; AST to platelets ratio
index [APRI]) and other laboratory values, as well as liver stiffness
measure and controlled attenuation parameter via transient elasto-
graphy (FibroScan®, Echosens, Paris, France). The Toolbox will
leverage the high negative predictive value of these non-invasive tests
to assess individual risk of fibrotic NASH [37–39]. For each test, the
Toolbox classifies risk as low, intermediate, or high. These outputs help
inform pre-screening at sites, indicating patients at a low probability of
passing the histological threshold for trial inclusion, and therefore
helping investigators select appropriate patients and minimize the
number of “low inclusion probability” patients undergoing liver biop-
sies during screening.
3.4. Randomization
Randomization will be performed centrally using an interactive
response system. In Part 1, at baseline (Day 1), eligible subjects will be
assigned to treatment arms (2:1 CVC or placebo) using permuted block
randomization stratified by NASH CRN fibrosis stage (F2 or F3) and the
presence or absence of documented T2DM (“yes” or “no”). Additional
subjects in Part 2 will be randomized at Part 2 baseline (Day 1) using
the same method, and stratified only based on presence or absence of
documented T2DM.
3.5. Study drug administration
Subjects will take one 150 mg tablet of study drug (double-blinded
CVC or placebo) daily with food. Subjects, investigators, and all site
personnel will be blinded to CVC and placebo individual treatment
assignment until Part 2 is complete and the database has been locked.
Blinding will be accomplished by the sponsor providing the study drug,
and packaging for active and placebo products will be identical apart
from a unique bottle identification number on the label. Data will be
unblinded at the end of Part 1 to allow for data analysis, although in-
dividual subject treatment assignments will not be provided to sites or
subjects until the analysis of Part 2 is completed. Emergency unblinding
may take place where immediate knowledge of the treatment received
(CVC versus placebo) is necessary for the management of the subject
and may be requested via the interactive response system.
4. Study assessments
4.1. Efficacy assessments
Liver biopsies will be performed at screening, and at Months 12 and
60, to evaluate the histological features of NASH, including fibrosis
stage (using both NASH CRN and modified Ishak systems). The liver
biopsy for each subject will be evaluated by an independent central
pathologist that is blinded to treatment arm designation and without
regard to histology assessments performed at any previous timepoints;
if possible, the same pathologist will evaluate all biopsies from an in-
dividual subject.
The NASH CRN uses a defined and validated semiquantitative
scoring system [40], the NAFLD activity score (NAS), which is used to
assess overall histological change based on an unweighted sum of
grades of steatosis (0–3), lobular inflammation (0–3), and hepatocel-
lular ballooning (0–2). Histopathological diagnosis of NASH requires
the presence of steatosis, lobular inflammation, and ballooning in a
characteristic pattern, and will be determined by the central patholo-
gist. The NASH CRN fibrosis staging system will be used to score fibrosis
stage as follows: none (Stage F0); perisinusoidal or periportal (Stage
F1); mild, zone 3, perisinusoidal (Stage F1a); moderate, zone 3, peri-
sinusoidal (Stage F1b); portal/periportal only (Stage F1c); perisinu-
soidal and portal/periportal (Stage F2); bridging fibrosis (Stage F3);
and cirrhosis (Stage F4) [40].
As the original Ishak staging system was designed for chronic viral
hepatitis [41], a modified Ishak system will be used to classify NASH
fibrosis stage, as it provides additional granularity at higher fibrosis
stages. Stages F0–F2 will use the same histologic definitions as the
NASH CRN system (without further classification of Stage F1 into F1a,
F1b, or F1c), and Stages F3–F6 will be defined as follows: occasional
bridging fibrosis (< 50% linkage of portal and/or central zones) [Stage
F3]; marked bridging fibrosis (> 50% linkage of portal and/or central
zones but not yet cirrhosis) [Stage F4]; early or incomplete cirrhosis
(Stage F5); and established or advanced cirrhosis (Stage F6) [42].
4.2. Patient-reported outcomes
Three patient-reported outcomes measures will assess change in
health outcomes from baseline: the Chronic Liver Disease Questionnaire
– Nonalcoholic Fatty Liver Disease (CLDQ-NAFLD-NASH) [43], Work
Productivity and Activity Impairment in NASH (WPAI-NASH) [44], and
36-Item Short Form Health Survey (SF-36) version 2 (health-related
quality of life index) [45,46]. Data will be collected at baseline, Months
6 and 12 for Part 1; at baseline and Month 12 for newly randomized
subjects in Part 2; and annually thereafter for all study subjects.
4.3. Safety assessments
Adverse events (AEs) will be assessed at each study visit and clas-
sified as shown in Table 2. AEs of special interest include elevations in
biochemistry associated with liver injury. Various laboratory tests will
be performed periodically throughout the study, and confirmation of
compliance with eligibility criteria regarding concomitant medications
and alcohol consumption will be obtained at each study visit. Popula-
tion pharmacokinetics of CVC will also be assessed: pre-dose and 1 h
post-dosing plasma samples will be collected at Months 3 and 12 of Part
1; at Month 6, plasma samples will be collected pre-dose and 2–6 h post
dosing.
An independent data and safety monitoring board will review the
safety data from the study. An independent adjudication committee will
review all events which may potentially contribute to the Part 2 pri-
mary endpoint; only events confirmed by the adjudication committee
will be included in this analysis.
4.4. Study discontinuation
The study drug will be discontinued in the following instances:
suspected drug-induced liver injury (criteria based on ALT and AST
elevations); unacceptable toxicity; acute viral hepatitis (hepatitis A, B,
C, D, or E), autoimmune or alcoholic hepatitis, hypoxic/ischemic he-
patopathy, or biliary tract disease during the study; hepatocellular
carcinoma; liver transplant; pregnancy; a subject requests to dis-
continue treatment for any reason; and discontinuation of the study at
the request of the sponsor, a regulatory agency, institutional review
board, independent ethics committee, or data and safety monitoring
board.
The drug will be permanently discontinued if a confirmed Grade 4
(life-threatening) laboratory abnormality or clinical event is considered
related to study drug, or if AST or ALT elevations meet the following
criteria upon repeat testing within 48–72 h:> 3 × ULN and >
5 × baseline measure, if baseline value<2 × ULN;>3 × baseline
measure, if baseline value 2≤ ULN < 5; or > 2 × baseline measure,
if baseline value≥5 × ULN (ULN range: 31–37 U/L for AST; 32–43 U/
L for ALT). Dosing should be interrupted if a confirmed Grade 3 la-
boratory abnormality or clinical event is considered related to study
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drug. For laboratory abnormalities or clinical events considered un-
related to study drug, the drug may be continued at the discretion of the
investigator, with appropriate follow up and management.
For subjects who discontinue study participation, every effort will
be made to ensure that they return for early discontinuation procedures
within 48 h. These subjects will also be required to return to the clinic
30 days after the last dose of study drug for a follow-up visit. If feasible,
and if the study drug was received for at least 6 months, this visit should
include a biopsy. Subjects who discontinue will be encouraged to
continue with all other evaluations as scheduled in the protocol.
4.5. Statistical analyses
For Part 1, two-sided 95% CI for the proportion who meet the pri-
mary efficacy endpoint will be calculated using Wilson's method for CI.
The key secondary endpoint will be tested only when the primary
endpoint result is significant (Table 1). The surrogate endpoint will be
tested at 0.0012 (two-sided) level to manifest strong evidence from a
single confirmatory study, and 0.048 (two-sided) level for study suc-
cess. Cochran–Mantel–Haenszel tests will be used, stratified by fibrosis
stage (F2 or F3) and presence or absence of T2DM at baseline, to
compare the rates in the two randomized treatment arms. The primary
efficacy endpoint will be evaluated in the modified intent-to-treat
(mITT) population (all subjects in the intent-to-treat [ITT] analysis set
who received at least one dose of the study drug), and sensitivity
analyses will be performed using the ITT and per-protocol populations.
Exploratory efficacy endpoints will be summarized by randomized
treatment group using descriptive statistics for the mITT set.
The Part 2 analysis will take place when adjudicated events have
been accrued in approximately 367 unique subjects. Time-to-event
analyses will be performed using the Kaplan–Meier product-limit
method and will be analyzed with the stratified logrank test, stratified
by fibrosis stage and presence or absence of T2DM at baseline, to
compare the rates between treatment arms (mITT analysis set). To
manifest strong evidence from a single confirmatory study, a sig-
nificance level of 0.00125 (two-sided) will be used if the test of the
surrogate endpoint in Part 1 is successful; a level of 0.00005 (two-sided)
will be used otherwise. For study success, a 0.05 (two-sided) sig-
nificance level will be used if the test of the surrogate endpoint is
successful and a 0.002 (two-sided) level will be used otherwise.
Analysis of Part 2 efficacy endpoints will use similar methods to Part 1.
Exploratory efficacy endpoints will be summarized by randomized
treatment group using descriptive statistics (mITT analysis set).
4.6. Missing data
For the Part 1 primary efficacy analysis, any available liver biopsy
obtained after receipt of at least 6 months of assigned study drug but
before 15 months of follow up may be used for the Month 12 biopsy.
For subjects with multiple liver biopsies, the evaluable biopsy closest to
the Month 12 visit will be used. Subjects without an evaluable liver
biopsy at both screening and Month 12 will be included as non-re-
sponders. Sensitivity analyses will account for both “missing at
random” and “missing not at random” scenarios.
For the Part 2 primary efficacy analysis, any available liver biopsy
after baseline may be used. If a subject has any biopsy that meets the
primary endpoint definition (determined by the adjudication com-
mittee), this will be included as an event. Subjects without evaluable
biopsies at screening and post baseline will be included as non-events,
unless they meet criteria for a primary endpoint component unrelated
to the biopsy. A sensitivity analysis assuming data are “missing not at
random” will be reported [47].
5. Discussion
As there are currently no approved treatments specifically for
NASH, the AURORA CVC Phase 3 study is an important clinical trial in
this disease area. The AURORA population consists of subjects shown to
be more likely to benefit from treatment – those with Stage F2 or F3
fibrosis – following results from the Phase 2b CENTAUR study which
demonstrated significant improvements in fibrosis in this group after
1 year of treatment [29].
This design has a number of advantages. The primary endpoint (the
proportion of subjects with improvement in fibrosis by≥1 stage [NASH
CRN system] and no worsening of steatohepatitis) is measurable, sen-
sitive to change and the effects of treatment, and is consistently quan-
tifiable [48,49]. Although there are currently no validated surrogate
endpoints for NASH, published evidence already supports the assertion
that fibrosis stage is an independent predictor of mortality [32,50]; in
this context, it is plausible that any sustained improvement in fibrosis
observed in this trial has important implications regarding improved
hard outcomes such as liver-related mortality. The histological surro-
gate endpoints used in this trial may therefore predict clinical benefit in
preventing cirrhosis and death.
Table 2
Adverse events.
AE terminology Definition
AE Any untoward medical occurrence in a subject administered a pharmaceutical product, which does not necessarily have a causal
relationship with this treatment
AE classificationa
Grade 1 (mild) Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
Grade 2 (moderate) Minimal, local, or non-invasive intervention indicated; limiting instrumental activities of daily living
Grade 3 (severe) Medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care activities
Grade 4 (life-threatening) Life-threatening consequences; urgent intervention indicated
Grade 5 (death) Death related to the AE
Treatment-emergent adverse event An AE beginning on or after the date of the first dose of study drug, or an exacerbation of a chronic or intermittent pre-existing
condition, up until 30 days after the last dose of study drug
Serious adverse event AE resulting in death, immediate risk of death (life-threatening), hospitalization, persistent or significant incapacity, congenital
anomaly, or important medical event requiring medical or surgical intervention to prevent the above
AE of special interest In this study, these include elevations in biochemistry associated with liver injury
AE assessed as related to study drug Temporal relationship between AE onset and administration of the study drug that cannot be readily explained by the subject's clinical
state or concomitant therapies
Furthermore, the AE appears with some degree of certainty to be related, based on the known therapeutic and pharmacologic actions
or AE profile of the study drug. If the dose is reduced or drug withdrawn, the AE abates or resolves, and reappears upon rechallenge
AE assessed as not related to study drug Evidence exists that the AE has an etiology other than the study drug; for serious AEs, an alternative causality must be provided (e.g.
pre-existing condition, underlying disease, intercurrent illness, concomitant medication)
AE, adverse event; NCI, National Cancer Institute.
a Classification according to NCI Common Terminology Criteria for Adverse Events.
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Use of histological methods to assess clinical benefit also serves as a
limitation of the design, as liver biopsies are invasive, can be painful,
are associated with risk of complications and may be subject to sam-
pling error [48,51]. However, liver biopsy is currently the only reliable
and generally accepted method for assessing the severity of NASH [52].
With this in mind, non-invasive markers may prove useful for sup-
porting evidence of efficacy [48,49], which is reflected in the choice of
secondary endpoints [53]. They may also be useful in optimizing sub-
ject selection, as per the AURORA Toolbox, which provides a novel and
innovative method for classifying subjects' a priori risk for clinically
significant fibrotic NASH, aiding pre-screening efforts by investigators
and potentially reducing the need for screening biopsies.
While there are currently no approved treatments for NASH, obe-
ticholic acid, resmetirom, and elafibranor are also undergoing clinical
investigations in Phase 3 trials in the setting of non-cirrhotic NASH,
with similar development timelines (NCT02548351 [REGENERATE];
NCT03900429 [MAESTRO-NASH]; NCT02704403 [RESOLVE-IT], re-
spectively). However, to date, comprehensive study designs have only
been published for REGENERATE [54].
In conclusion, the AURORA Phase 3 study has been carefully de-
signed based on the clinically meaningful results of the well-powered
Phase 2b CENTAUR study to ensure a comprehensive assessment of the
efficacy and safety of CVC treatment compared to placebo in adult
subjects with NASH and Stage F2 or F3 liver fibrosis. This assessment is
consistent with the recently recommended baseline assessments of pa-
tients in NASH trials for harmonizing clinical trial data across trials [3].
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